{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:25:04Z","timestamp":1783103104304,"version":"3.54.6"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","award":["T32 CA233414"],"award-info":[{"award-number":["T32 CA233414"]}],"id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["KC230193"],"award-info":[{"award-number":["KC230193"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5R01CA269349"],"award-info":[{"award-number":["5R01CA269349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106908","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:31:50Z","timestamp":1776720710000},"page":"106908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid\/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-1151","authenticated-orcid":false,"given":"N.","family":"Savion-Gaiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-612X","authenticated-orcid":false,"given":"D.G.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bar-Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Djureinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-6334","authenticated-orcid":false,"given":"I.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9820-632X","authenticated-orcid":false,"given":"A.","family":"Adeniran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.esmoop.2026.106908_bib1","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Rini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106908_bib2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106908_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106908_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106908_bib6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106908_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106908_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106908_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106908_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"El Zarif","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106908_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41379-019-0269-x","article-title":"JAK2\/PD-L1\/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management","volume":"32","author":"Gupta","year":"2019","journal-title":"Mod Pathol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106908_bib14","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1002\/cncr.30937","article-title":"Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation","volume":"123","author":"Kawakami","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106908_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106908_bib17","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1538-7445.AM2024-5151","article-title":"High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma","volume":"84","author":"Vemula","year":"2024","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib18","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s11255-021-02841-7","article-title":"Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer","volume":"53","author":"M\u00f6ller","year":"2021","journal-title":"Int Urol Nephrol"},{"issue":"49","key":"10.1016\/j.esmoop.2026.106908_bib19","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106908_bib20","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106908_bib21","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106908_bib23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-23-2274","article-title":"PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from anti-PD-1 therapy in metastatic clear-cell renal cell carcinoma patients","volume":"30","author":"Denize","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106908_bib24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","article-title":"Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma","volume":"15","author":"Hugaboom","year":"2025","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106908_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007240","article-title":"Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases","volume":"11","author":"Schoenfeld","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106908_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.106908_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.890410","article-title":"Challenges and opportunities for immunoprofiling using a spatial high-plex technology: the nanoString GeoMx\u00ae digital spatial profiler","volume":"12","author":"Hernandez","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"11","author":"Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106908_bib30","doi-asserted-by":"crossref","first-page":"24990","DOI":"10.18632\/oncotarget.4572","article-title":"Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens","volume":"6","author":"Baine","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7150\/jca.8167","article-title":"PD-L1 Expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases","volume":"5","author":"Jilaveanu","year":"2014","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106908_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14737159.2019.1680286","article-title":"Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review","volume":"20","author":"Rebuzzi","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106908_bib33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2020.10.006","article-title":"The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis","volume":"79","author":"Mori","year":"2021","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106908_bib34","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-22-0923","article-title":"Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma","volume":"28","author":"Denize","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106908_bib35","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"issue":"54","key":"10.1016\/j.esmoop.2026.106908_bib36","doi-asserted-by":"crossref","first-page":"93156","DOI":"10.18632\/oncotarget.21114","article-title":"Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13000-023-01320-0","article-title":"B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis","volume":"18","author":"Lee","year":"2023","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib38","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1186\/s12885-024-13238-x","article-title":"Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response","volume":"24","author":"\u00d6zalp","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 inhibitors in oncology clinical trials: a review","volume":"7","author":"Feustel","year":"2024","journal-title":"J Immunother Precis Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib40","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41590-024-02014-5","article-title":"A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer","volume":"25","author":"Guanizo","year":"2024","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106908_bib42","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1349-7006.2011.01945.x","article-title":"Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma","volume":"102","author":"Komohara","year":"2011","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00428-016-1973-2","article-title":"Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma","volume":"469","author":"Cros","year":"2016","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106908_bib44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106908_bib45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-022-03266-6","article-title":"Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma","volume":"72","author":"Lauridsen","year":"2023","journal-title":"Cancer Immunol Immun"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106908_bib47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.34281","article-title":"CD25: A potential tumor therapeutic target","volume":"152","author":"Peng","year":"2023","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.esmoop.2026.106908_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106908_bib50","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1111\/febs.14524","article-title":"Cancer-related circulating and tumor-associated neutrophils - subtypes, sources and function","volume":"285","author":"Shaul","year":"2018","journal-title":"Febs J"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106908_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.it.2015.11.008","article-title":"Neutrophils in the tumor microenvironment","volume":"37","author":"Powell","year":"2016","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12307-014-0147-5","article-title":"The multifaceted roles neutrophils play in the tumor microenvironment","volume":"8","author":"Sionov","year":"2015","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.esmoop.2026.106908_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101866","article-title":"Tumor associated neutrophils governs tumor progression through an IL-10\/STAT3\/PD-L1 feedback signaling loop in lung cancer","volume":"40","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106908_bib54","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106908_bib55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmoop.2026.106908_bib56","doi-asserted-by":"crossref","first-page":"S1023","DOI":"10.1016\/j.annonc.2024.08.1800","article-title":"A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma","volume":"35","author":"Saad","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:09:28Z","timestamp":1783102168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926008501"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106908","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid\/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106908"}}